Xuan Zhang Source Confirmed

OverviewAI-generated summary

Xuan Zhang leads a research group focused on investigating the pharmacological effects and therapeutic potential of various compounds. Their work includes studying natural products and their mechanisms of action in disease models. Recent publications investigate cepharanthine as a selective ANO1 inhibitor for lung adenocarcinoma therapy, the protective effects of 1,8-cineole against heart failure by inhibiting oxidative and ER stress, and how escin ameliorates depressive-like behavior in rats via specific signaling pathways.

Further research explores the identification of evodiamine and rutecarpine as TMEM16A inhibitors and their effects on isolated guinea-pig ileum. Additionally, Zhang's group has published on neferine's protective role against hypoxia/reoxygenation injury in cardiomyocytes through SIRT1/Nrf2/HO-1 signaling. Their analytical capabilities are demonstrated through a publication on the rapid screening of pesticide residues in chrysanthemum flower using gas chromatography coupled to mass spectrometry. Zhang also co-authored a meta-analysis on biologic TNF-α inhibitors for severe cutaneous adverse drug reactions like Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis.

Zhang has an h-index of 25 and has authored over 80 publications, accumulating more than 2,100 citations. They are recognized as a highly cited researcher and remain recently active in their field.

Metrics

• h-index: 25
• Publications: 80
• Citations: 2,186